San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

HIMS stock up 16% on Wednesday, continuing month-long gains. Novo Nordisk ends partnership, cites misleading marketing and ...

Novo Nordisk announced it is cutting ties with telehealth giant Hims & Hers Health, pulling its blockbuster drug Wegovy from the platform after accusing the company of selling “illegitimate, knockoff ...

Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending shares of the U.S. telehealth company plunging more than 30%.

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic versions of Novo Nordisk’s lucrative semaglutide drugs for diabetes and obesi | ...

This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth company Hims & Hers Health (NYSE: HIMS), citing concerns over Hims & Hers’ ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

Hims & Hers Health Inc. board members and executives failed to tell shareholders that its Novo Nordisk A/S Wegovy ...

The market for generic GLP-1 weight loss drugs in Canada is set to open up, and Hims & Hers is ready to jump in.  | Novo ...

EPA-EFE/Ida Marie Odgaard DENMARK OUT July 9 (UPI) --The Hims & Hers wellness platform announced Wednesday it will soon offer ...

Hims & Hers was founded in 2017, known as just “Hims” at the time, as a platform for men to get prescriptions online for erectile dysfunction and hair loss medications.

Hims & Hers’ stock price has swung wildly this year. The price had at one point soared more than 150% this year before the Novo split knocked off a nearly a third of its valuation on Monday.